Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2014

01-10-2014 | Review

Therapeutic potential of siRNA and DNAzymes in cancer

Authors: Hanuma Kumar Karnati, Ravi Shekar Yalagala, Rambabu Undi, Satya Ratan Pasupuleti, Ravi Kumar Gutti

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

Cancer is characterized by uncontrolled cell growth, invasion, and metastasis and possess threat to humans worldwide. The scientific community is facing numerous challenges despite several efforts to cure cancer. Though a number of studies were done earlier, the molecular mechanism of cancer progression is not completely understood. Currently available treatments like surgery resection, adjuvant chemotherapy, and radiotherapy are not completely effective in curing all the cancers. Recent advances in the antisense technology provide a powerful tool to investigate various cancer pathways and target them. Small interfering RNAs (siRNAs) could be effective in downregulating the cancer-associated genes, but their in vivo delivery is the main obstacle. DNA enzymes (DNAzymes) have great potential in the treatment of cancer due to high selectivity and significant catalytic efficiency. In this review, we are focusing on antisense molecules such as siRNA and DNAzymes in cancer therapeutics development. This review also describes the challenges and approaches to overcome obstacles involved in using siRNA and DNAzymes in the treatment of cancers.
Literature
1.
Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515–9.PubMed
2.
Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003;545:144–50.PubMedCrossRef
3.
Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–11.PubMedCrossRef
4.
Bernstein E, Caudy A, Hammond S, Hannon G. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–6.PubMedCrossRef
5.
6.
Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101:25–33.PubMedCrossRef
7.
Vermeulen A, Behlen L, Reynolds A, Wolfson A, Marshall WS, Karpilow J, et al. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA. 2005;11:674–82.PubMedCentralPubMedCrossRef
8.
Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A. 1985;82:1810–4.PubMedCentralPubMedCrossRef
9.
Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 1985;229:1390–3.PubMedCrossRef
10.
Finger LR, Harvey RC, Moore RCA, Showe LC, Croce CM. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science. 1986;234:982–5.PubMedCrossRef
11.
12.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.PubMedCrossRef
13.
Nakamura E, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002;10:1119–28.PubMedCrossRef
14.
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7:31–9.PubMedCrossRef
15.
Kim DY, Kim MJ, Kim HB, Lee JW, Bae JH, Kim DW, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta. 1812;2011:796–805.
16.
17.
18.
Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982;297:474–8.PubMedCrossRef
19.
Gambke C, Signer E, Moroni C. Activation of N-ras gene in bone marrow cells from a patient with acute myeloblastic leukaemia. Nature. 1984;307:476–8.PubMedCrossRef
20.
Xue-mei S, Graham JL. Abnormal protein tyrosine kinases associated with human haematological malignancies. Chin J Cancer Res. 2002;14:79–83.CrossRef
21.
Blume JP, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.CrossRef
22.
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.PubMedCrossRef
23.
Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.PubMedCrossRef
24.
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, et al. Contributions of the Raf/MEK/ERK, P13K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22:686–707.PubMedCrossRef
25.
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.PubMedCrossRef
26.
Alumbres M. Barbacid M RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.CrossRef
27.
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.PubMedCrossRef
28.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef
29.
30.
Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22:9007–21.PubMedCrossRef
31.
Macauley VM, Sohail M. Molecular targeting of the IGF-1 receptor. 2005; US20040996951.
32.
Khvorova A, Reynolds A, Leake D, et al. siRNA targeting insulin-like growth factor 1 receptor (IGF-1R). 2007; US20070732457.
33.
Evers BM, Rychahou P. SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy. 2005; US20050085962.
34.
35.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–86.PubMedCrossRef
36.
Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27:85–94.PubMedCrossRef
37.
Shinomiya N, Woude GFV. c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity. 2007; US20050599327.
38.
Khvorova A, Reynolds A, Leake D, et al. siRNA targeting proto-oncogene MET. 2008; US20070980263.
39.
Kraus MH, Pierce JH, Fleming TP, Robbins KC, Di Fiore PP, Aaronson SA. Mechanisms by which genes encoding growth factors and growth factor receptors contribute to malignant transformation. Ann N Y Acad Sci. 1988;551:320–35.PubMedCrossRef
40.
Khvorova A, Reynolds A, Leake D, et al. siRNA targeting platelet-derived growth factor receptor beta polypeptide (PDGFR). 2008; US20070731890.
41.
Mc Swiggen J, Beigelman L, Chowrira BM. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid. 2003;WO 2003072704 A2
42.
Reich SJ, Tolentino MJ. Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2. 2004; US20040827759.
43.
Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225–34.PubMedCrossRef
44.
Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis. 2003;9:210–6.PubMed
45.
Lu PY, Xie FY, Woodle MC. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med. 2005;11:104–13.PubMedCrossRef
46.
Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 2006;13:559–62.PubMedCrossRef
47.
Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, et al. Inhibition of cathepsin B and MMP 9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene. 2004;23:4681–9.PubMedCrossRef
48.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Auguri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–81.PubMedCrossRef
49.
Khvorova A, Reynolds A, Leake D, et al. Functional and hyperfunctional siRNA directed against Bcl-2. 2008; US20070974878.
50.
McSwiggen J, Beigelman L. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA). 2005; US20040923516
51.
Wang K, Chen X, Yan F, Xing Y, Yang X, Tu J, et al. 5′-Triphosphate-siRNA against surviving gene induces interferon production and inhibits proliferation of lung cancer cells in vitro. J Immunother. 2013;36:294–304.PubMedCrossRef
52.
Adhim Z, Otsuki N, Kitamoto J, Morishita N, Kawabata M, Shirakawa T, et al. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines. Acta Otolaryngol. 2013;3:761–71. doi:10.​3109/​00016489.​2013.​773405.CrossRef
53.
54.
Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther. 2006;17:117–24.PubMedCrossRef
55.
56.
Todorovic V, Sersa G, Cemazar M. siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28. Cancer Gene Ther. 2013;20:208–10.PubMedCrossRef
57.
Wiktorska M, Sacewicz-Hofman I, Stasikowska-Kanicka O, Danilewicz M, Niewiarowska J. Distinct inhibitory efficiency of siRNAs and DNAzymes to β1 integrin subunit in blocking tumor growth. Acta Biochim Pol. 2013;60:77–82.PubMed
58.
Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther. 2005;12:634–43.PubMedCrossRef
59.
Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA–lipoplexes for cancer therapy. Gene Ther. 2006;13:1360–70.PubMedCrossRef
60.
Kristina W, Thiel L, Hernandez I, Dassie JP, Thiel WH, Xiuying L, et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012;40:6319–37.CrossRef
61.
Pillé JY, Li H, Blot E, Bertrand JR, Pritchard LL, Opolon P, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther. 2006;17:1019–26.PubMedCrossRef
62.
Hu K, Law JH, Fotovati A, Dunn SE. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 2012;14:R22.PubMedCentralPubMedCrossRef
63.
Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 2013;73:1709–20.PubMedCrossRef
64.
Yin R, Hiu WC, Geoffrey VM, Amit A, Glenn SC, Barbara AW, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Cancer. 2012;4:147ra112.
65.
Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 2004;10:7721–6.PubMedCrossRef
66.
67.
He W, Liu T, Chen YX, Cheng DJ, Li XR, Xiao Y, et al. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther. 2008;15:193–202.PubMedCrossRef
68.
Liu K, Chen H, You Q, Shi H, Wang Z. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem. 2014;386:117–24.PubMedCentralPubMedCrossRef
69.
70.
Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel SF, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751–66.PubMedCrossRef
71.
Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK, Fassett D, et al. Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther. 2010;9:2605–17.PubMedCentralPubMedCrossRef
72.
Yang L, Lu Z, Ma X, Cao Y, Sun LQ. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules. 2010;15:6127–39.PubMedCrossRef
73.
Lu ZX, Ma XQ, Yang LF, Wang ZL, Zeng L, Li ZJ, et al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett. 2008;265:226–38.PubMedCrossRef
74.
75.
Yang L, Xu Z, Liu L, Luo X, Lu J, Sun L, et al. Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity. Cancer Biol Ther. 2014;15:61–8.PubMedCentralPubMedCrossRef
76.
Shen L, Zhou Q, Wang Y, Liao W, Chen Y, Xu Z, et al. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme. Mol Med. 2013;19:377–86.PubMedCentralPubMedCrossRef
77.
Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumor growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res. 2004;32:3065–9.PubMedCentralPubMedCrossRef
78.
Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med. 2003;9:1026–32.PubMedCrossRef
79.
Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res. 2002;62:5463–9.PubMed
80.
Hallet MA, Teng B, Hasegawa H, Schwab LP, Seagroves TN, Pourmotabbed T. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res. 2013;15:R12.CrossRef
81.
Zeng W, Deng L, Zhou R. Experimental study of targeting MMP-9 deoxyribozyme role of adhesion and migration in human lung adenocarcinoma cancer cell (in Chinese). Chin J Lung Cancer. 2008;11:765–8.
82.
Yang L, Zeng W, Li D, Zhou R. Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol Rep. 2009;22:121–6.PubMedCrossRef
83.
Min Z, Zhao H, Luo FY, Luo S, Shi W. IGF-II inhibitory DNAzymes inhibit the invasion and migration of hepatocarcinoma cells. Biotechnol Lett. 2011;33:911–7.PubMedCrossRef
84.
Liang ZY, Wei SZ, Guan J, Luo Y, Gao J, Zhu H, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. J Gastroenterol Hepatol. 2005;20:1595–602.PubMedCrossRef
85.
Wiktorska M, Papiewska-Pajak L, Okruszek A, Sacewicz-Hofman I, Neiwiarowska J. DNAzyme as an efficient tool to modulate invasiveness of human carcinoma cells. Acta Biochim Pol. 2010;57:269–75.PubMed
86.
Choi BR, Gwak J, Kwon HM, Oh S, Kim KP, Choi WHH, et al. Oligodeoxyribozymes that cleave β catenin messenger RNA inhibit growth of colon cells via reduction of β-catenin response transcription. Mol Cancer Ther. 2010;9:1894–902.PubMedCrossRef
87.
Yu SH, Wang TH, Au LC. Specific repression of mutant K-RAS by 10–23 DNAzyme: sensitizing cancer cell to anti-cancer therapies. Biochem Biophys Res Commun. 2009;378:230–4.PubMedCrossRef
88.
Qu Y, Zhang L, Mao M, Zhao F, Huang X, Yang C, et al. Effects of DNAzymes targeting aurora kinase A on the growth of human prostate cancer. Cancer Gene Ther. 2008;15:517–25.PubMedCrossRef
89.
Nna E, Madukwe J, Egbujo E, Obiorah C, Okolie C, Echejoh G, et al. Gene expression of Aurora kinases in prostate cancer and nodular hyperplasia tissues. Med Princ Pract. 2013;22:138–43.PubMedCrossRef
90.
Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene. 2006;25:7260–6.PubMedCrossRef
91.
Wu Y, Yu L, Mcmahon R, Rossi JJ, Forman SJ, Snyder DS. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther. 1999;10:2847–57.PubMedCrossRef
92.
Kabuli M, Yin JL, Tobal K. Targeting PML/RARα transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells. Hematol J. 2005;5:426–33.CrossRef
93.
Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst. 2004;96:683–96.PubMedCrossRef
94.
Dass CR, Galloway SJ, Clark JC, Khachigian LM, Choong PF. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther. 2008;7:1297–301.PubMedCrossRef
95.
De Bock CE, Lin Z, Itoh T, Morris D, Murrel G, Wang Y. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J. 2005;272:3572–82.PubMedCrossRef
96.
Cai H, Santiago FS, Prado-Lourenco L, Wang B, Patrikakis M, Davenport MP, et al. DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med. 2012;4:139ra82.PubMedCrossRef
97.
Yang L, He JT, Guan H, Sun YD. AKT1 inhibitory DNAzymes inhibit cell proliferation and migration of thyroid cancer cells. Asian Pac J Cancer Prev. 2013;14:2571–5.PubMedCrossRef
98.
99.
Ma JB, Yuan YR, Meister G, Pei Y, Tuschl T, Patel DJ. Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature. 2005;434:666–70.PubMedCrossRefPubMedCentral
100.
Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20:6877–88.PubMedCentralPubMedCrossRef
101.
102.
Braasch DA, Jensen S, Liu YH, Kaur K, Arar K, White MA, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42:7967–75.PubMedCrossRef
103.
Hall AHS, Wan J, Shaughnessy EE, Shaw BR, Alexander KA. RNA interference using boranophosphate siRNAs: structure–activity relationships. Nucleic Acids Res. 2004;32:5991–6000.PubMedCentralPubMedCrossRef
104.
Martinez J, Tuschl T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Cancer Dev. 2004;18:975–80.
105.
Parrish S, Fleenor J, Xu S, Mello C, Fire A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell. 2000;6:1077–87.PubMedCrossRef
106.
Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem. 2005;48:4247–53.PubMedCrossRef
107.
108.
Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res. 2006;34:1669–75.PubMedCentralPubMedCrossRef
109.
Shen L, Zhang C, Ambrus JL, Wang JH. Silencing of human c-myc oncogene expression by poly-DNP-RNA. Oligonucleotides. 2005;15:23–35.PubMedCrossRef
110.
Elmen J, Thonberg H, Ljungberg K, Frieden M. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33:439–47.PubMedCentralPubMedCrossRef
111.
Dande P, Prakash TP, Sioufi N, Gaus H, Jarres R, Berdeja A, et al. Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J Med Chem. 2006;49:1624–34.PubMedCrossRef
112.
Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003;22:5938–45.PubMedCrossRef
113.
114.
115.
Tousignant JD, Gates AL, Ingram LA, Ohnson CL, Nietupski JB, Cheng SH, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum Gene Ther. 2000;11:2493–513.PubMedCrossRef
116.
Dass CR. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in vivo. J Pharm Pharmacol. 2002;54:593–601.PubMedCrossRef
117.
Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 2005;12:321–8.PubMedCrossRef
118.
Ahmad I, Zhang ZY, Zhang JA, et al. Lipid compositions and use thereof. 2005; CA20052559352.
119.
Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–7.PubMedCrossRef
120.
Mc Swiggen J, Morrissey D, Guerciolini R, et al. RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA). 2009; WO2006US62252.
121.
Czech B, Malone CD, Zhou R, Stark A, Schlingeheyde C, Dus M, et al. An endogenous small interfering RNA pathway in Drosophila. Nature. 2008;453:798–802.PubMedCentralPubMedCrossRef
122.
Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12:461–6.PubMedCrossRef
123.
Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, August JT, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release. 1998;53:183–93.PubMedCrossRef
124.
Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007;121:64–73.PubMedCrossRef
125.
Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32:e149.PubMedCentralPubMedCrossRef
126.
Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem. 2004;15:831–40.PubMedCrossRef
127.
Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3:641–50.PubMedCrossRef
128.
Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr Med Chem. 2004;11:179–97.PubMedCrossRef
129.
O’Mahony AM, Desgranges S, Ogier J, Quinlan A, Devocelle M, Darcy R, et al. In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery. Pharm Res. 2013;30:1086–98.PubMedCrossRef
130.
Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006;14:476–84.PubMedCrossRef
131.
Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 2009;17:162–8.PubMedCentralPubMedCrossRef
132.
Hanai K, Takeshita F, Honma K, Nagahara S, Maeda M, Minakuchi Y, et al. Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann N Y Acad Sci. 2006;1082:9–17.PubMedCrossRef
133.
Takeshita F, Minakuchi Y, Nagahara S, Honna K, Sasaki H, Hirai K, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A. 2005;102:12177–82.PubMedCentralPubMedCrossRef
134.
Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004;32:e109.PubMedCentralPubMedCrossRef
135.
Inaba S, Nagahara S, Makita N, et al. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther. 2012;20:356–66.PubMedCentralPubMedCrossRef
136.
Song E et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–17.PubMedCrossRef
137.
138.
Hu-lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, noviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 2005;65:8984–92.PubMedCrossRef
139.
Wilner SE, Wengerter B, Maier K, de Lourdes Borba Magalhães M, Del Amo DS, Pai S, et al. An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids. 2012;1(5):e21.PubMedCentralPubMedCrossRef
140.
Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, et al. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci U S A. 2008;105:15908–13.PubMedCentralPubMedCrossRef
141.
Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release. 2008;131:64–9.PubMedCentralPubMedCrossRef
142.
Achenbach JC, Chiuman W, Cruz RP, Li Y. DNAzymes: from creation in vitro to application in vivo. Curr Pharm Biotechnol. 2004;5:321–36.PubMedCrossRef
143.
Wang Y, Xu Z, Guo S, et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther. 2013;21:1919–29.PubMedCentralPubMedCrossRef
144.
Yang XZ, Dou S, Wang YC, et al. Single-step assembly of cationic lipid–polymer hybrid nanoparticles for systemic delivery of siRNA. ACS Nano. 2012;6:4955–65.PubMedCrossRef
145.
Schlegel A, Bigey P, Dhotel H, Scherman D, Escriou V. Reduced in vitro and in vivo toxicity of siRNA-lipoplexes with addition of polyglutamate. J Control Release. 2013;165:1–8.PubMedCrossRef
146.
Asai T, Matsushita S, Kenjo E, et al. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA 145 delivery. Bioconjug Chem. 2011;22:429–35.PubMedCrossRef
147.
Schlegel A, Largeau C, Bigey P, et al. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J Control Release. 2011;152:393–401.PubMedCrossRef
148.
Bartel DP, Szostak JW. Isolation of a new ribozymes from a large pool of random sequences. Science. 1993;261:1411–8.PubMedCrossRef
149.
150.
Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry. 1998;37:13330–42.PubMedCrossRef
151.
Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature. 1990;344:467–8.PubMedCrossRef
152.
Perreault JP, Wu T, Cousineau B, Cedergren R. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature. 1990;344:565–7.PubMedCrossRef
153.
Yang JH, Usman N, Chartrand P, Robert C. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry. 1992;31:5005–9.PubMedCrossRef
154.
Paquette J, Nicoghosian K, Qi GR, Beauchemin N, Cedergren R. The conformation of single-stranded nucleic acids tDNA versus tRNA. Eur J Biochem. 1990;189:259–65.PubMedCrossRef
155.
Breaker RR, Joyce GF. DNA enzyme that cleaves RNA. J Chem Biol. 1994;1:223–9.CrossRef
156.
Geyer RC, Sen D. Evidence for the metal-cofactor independence of an RNA phosphodiester-cleaving DNA enzyme. J Chem Biol. 1997;4:579–93.CrossRef
157.
Perrin DM, Garestier T, Helene CJ. A ligand-modulated padlock oligonucleotide for supercoiled plasmids. Am Chem Soc. 2001;123:1556–63.CrossRef
158.
Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods. 1986;13:97–102.PubMedCrossRef
159.
Eder PS, Devine RJ, Dagle JM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev. 1991;1:141–51.PubMedCrossRef
160.
Sioud M, Leirdal M. Design of nuclease resistant protein kinase Ca DNA enzymes with potential therapeutic application. J Mol Biol. 2000;296:937–47.PubMedCrossRef
161.
Vaerman JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood. 1997;90:331–9.PubMed
162.
SunL Q, Cairns MJ, Gerlach WL, Witherington C, Wang L, King A. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem. 1999;274:17236–41.CrossRef
163.
Iversen PO, Nicolaysen G, Sioud M. DNA enzyme targeting TNFalpha mRNA improves hemodynamic performance in rats with post infarction heart failure. Am J Physiol Heart Circ Physiol. 2001;281:2211–7.CrossRef
164.
Iversen PO, Emanuel PD, Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood. 2002;99:4147–53.PubMedCrossRef
165.
Warashina M, Kuwabara T, Nakamatsu Y, Taira K. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. Chem Biol. 1999;6:237–50.PubMedCrossRef
166.
Cieslak M, Niewiarowska J, Nawrot M, Koziolkiewicz M, Stec WJ, Cierniewski C. DNAzymes to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and Matrigel. J Biol Chem. 2002;277:6779–87.PubMedCrossRef
167.
Takahashi H, Hamazaki H, Habu Y, Hayashi M, Abe T, Miyano-Kurosaki N, et al. A new modified DNA enzyme that targets influenza virus A. FEBS Lett. 2004;560:69–74.PubMedCrossRef
168.
Pun SH, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, et al. Biodistribution of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Can Biol Ther. 2004;3:641–50.CrossRef
169.
Levin A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta. 1999;1489:69–84.PubMedCrossRef
170.
Wengel J, Petersen M, Nielsen KE, Jensen GA, Hakansson AE, Kumar R. LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets. Nucleotides Nucleic Acids. 2001;20:389–96.CrossRef
171.
Petersen M, Wengel J. LNA a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003;21:74–81.PubMedCrossRef
172.
Crinelli R, Bianchi M, Gentilini L, Palma L, Magnani M. Locked nucleic acids (LNA) versatile tools for designing oligonucleotide decoys with high stability and affinity. Curr Drug Targets. 2004;5:745–52.PubMedCrossRef
173.
Jakobsen M, Haasnoot R, Wengel J, Berkhout J, Kjems B. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. J Retrovirol. 2007;4:1–13.CrossRef
174.
Schubert S, Fürste JP, Werk D, Grunert HP, Zeichhardt H, Erdmann VA, et al. Gaining target access for deoxyribozymes. J Mol Biol. 2004;339:355–63.PubMedCrossRef
175.
Doran G, Sohail M. Systemic analysis of the role of target site accessibility in the activity of DNA enzymes. J RNAi Gene Silenc. 2006;2:205–14.
176.
177.
Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, et al. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target. 2003;11:449–56.PubMedCrossRef
178.
179.
Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Roman CE, et al. Modified poly(propelene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). Drug Target. 2006;14:69–86.CrossRef
180.
Tack F, Noppe M, Van DA, Dekeyzer N, Leede BJ, Bakker A, et al. Delivery of a DNAzyme targeting c-myc to HT29 colon carcinoma cells using a gold nanoparticulate approach. Pharmazie. 2008;63:221–5.PubMed
181.
Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol. 2004;22:321–5.PubMedCrossRef
182.
Jackson AL, Burchard J, Reynolds A, Schelter J, Guo J, Johnson JM, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12:1179–87.PubMedCentralPubMedCrossRef
183.
Anderson EM, Birmingham A, Baskerville S, Baskerville S, Reynolds A, Maksimova E, et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA. 2008;14:853–61.PubMedCentralPubMedCrossRef
184.
Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3′ UTR seed matches, but not over all identity, are associated with RNAi target. Nat Methods. 2006;3:199–204.PubMedCrossRef
185.
Baum DA, Silverman SK. Deoxyribozymes: useful DNA catalysts in vitro and in vivo. Cell Mol Life Sci. 2008;65:2156–74.PubMedCrossRef
186.
Metadata
Title
Therapeutic potential of siRNA and DNAzymes in cancer
Authors
Hanuma Kumar Karnati
Ravi Shekar Yalagala
Rambabu Undi
Satya Ratan Pasupuleti
Ravi Kumar Gutti
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2477-9

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue

Research Article

RETRACTED ARTICLE: MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN

Research Article

MiR-26a inhibits prostate cancer progression by repression of Wnt5a

Research Article

Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma

Research Article

Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma

Research Article

Clinical significance of serum ferritin in elderly patients with primary lung carcinoma

Research Article

Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits